Delivery Order SPE2DB22D3016-SPE2DB25FBDD7
- Not listed
- The Defense Logistics Agency awarded a $12,726.40 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/mL syringes, with an ultimate completion date of July 28, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,459.35 to AmerisourceBergen Drug Corp for the supply of Prolia 60 mg/ml syringes. The contract, awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, utilizes firm fixed price terms and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery order at its corporate office...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a Firm Fixed Price Delivery Order contract worth $3,486.84 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Prolia 60 mg/mL syringes. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on July 18, 2025, valued at $14,789.72 for the supply of Prolia 60 mg/mL syringes. This firm fixed-price delivery order, which is set to be completed by July 21, 2025, was competitively awarded without set-aside provisions and is funded through the Medical Supply Chain, a defense-oriented federal agency. The award represents a child contract under...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $11,260.68 firm fixed-price delivery order is for the supply of Prolia 60 mg/mL syringes. The award has an ultimate completion date of September 27, 2024. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which...
- The Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of PROLIA 60 MG/ML SYRINGES. The contract has a potential value of $5,230.26 and a completion date of February 23, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, with no set-aside designation. Additionally, Amerisourcebergen Drug Corp holds an indefinite delivery...
- The Defense Logistics Agency Troop Support Medical awarded a $15,501.52 firm fixed price delivery order to Amerisourcebergen Drug Corporation for Prolia 60 mg/ml syringes. As the prime contractor, Amerisourcebergen Drug Corporation will deliver the requested pharmaceutical products to its place of performance in Conshohocken, Pennsylvania by August 10, 2023 under the terms of the contract. The Defense Logistics Agency supports Department of Defense health care programs and manages the global...
- Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, was awarded a $5,410.00 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) Troop Support Medical to provide PROLIA 60 MG/ML SYRINGEML. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00, which serves as the primary vehicle for Amerisourcebergen to deliver pharmaceuticals and medical supplies to DLA Troop Support Medical facilities...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Prolia 60 mg/ml syringes. The contract has a completion date of February 6, 2024 and a potential value of $3,486.84. Amerisourcebergen Drug Corp serves as a prime contractor providing a wide range of pharmaceutical products and medical supplies to U.S. government agencies, particularly the...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $40,226.07, is a delivery order for the supply of Prolia 60 mg/ml syringes. The contract has an ultimate completion date of April 15, 2025 and is a firm fixed-price contract. There is no set-aside designation for this award. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBDD7Delivery Order
The Defense Logistics Agency awarded a $36,928.09 delivery order to AmerisourceBergen Drug Corp for Prolia 60 mg/ml syringes, with an ultimate completion date of July 28, 2025. This is a firm fixed-price, non-set-aside contract executed on July 26, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical support vehicle valued through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capacity to fulfill diverse pharmaceutical and medical supply requirements through open competition, supplying medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency operations, the U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.9k | 7/26/25 |